Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
9.55
-0.93 (-8.87%)
Dec 5, 2025, 1:37 PM EST - Market open
Personalis Revenue
Personalis had revenue of $14.50M in the quarter ending September 30, 2025, a decrease of -43.62%. This brings the company's revenue in the last twelve months to $69.10M, down -21.02% year-over-year. In the year 2024, Personalis had annual revenue of $84.61M with 15.15% growth.
Revenue (ttm)
$69.10M
Revenue Growth
-21.02%
P/S Ratio
12.80
Revenue / Employee
$301,760
Employees
229
Market Cap
848.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 84.61M | 11.13M | 15.15% |
| Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
| Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
| Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
| Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
| Dec 31, 2019 | 65.21M | 27.43M | 72.62% |
| Dec 31, 2018 | 37.77M | 28.38M | 302.15% |
| Dec 31, 2017 | 9.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PSNL News
- 16 days ago - Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 25 days ago - Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer - Business Wire
- 4 weeks ago - Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Personalis Reports Third Quarter 2025 Financial Results - Business Wire
- 6 weeks ago - Personalis to Announce Third Quarter 2025 Financial Results - Business Wire
- 7 weeks ago - Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing - Business Wire
- 2 months ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test - Business Wire